While telehealth startups burn cash on flashy marketing, a 203-person laboratory in an undefined region is generating $31.5M annually by solving the unsexy, critical problem of substance compliance. Drugscan.com isn't chasing viral moments—it's managing the invisible infrastructure of opioid therapy and antiepileptic monitoring.

"This isn't a consumer-facing startup—it's a B2B utility that owns the regulatory compliance layer for substance monitoring."

The leadership team reads like a toxicology textbook: Deborah Motika (Sr VP Toxicology), Wendy Adams (Lab Director), and Michael Welsh (Quality Assurance). This isn't a tech-first team—it's a science-first operation building defensible moats through regulatory expertise. The absence of funding data suggests either private ownership or self-sufficiency, both rare in today's venture-hungry healthtech landscape.

• Revenue per employee: ~$155K—efficient for a lab operation
• Traffic quality over quantity: 3,126 visits driving $31.5M
• Direct traffic dominance: 40% indicates strong institutional relationships
• Clinical keyword strategy: Targets compliance, not consumer curiosity